Uncategorized
CLS-TA meets primary, secondary endpoints in phase 2 clinical trial
CLS-TA has met its primary endpoint of achieving a statistically significant mean change in central subfield thickness from baseline in the phase 2 Dogwood trial, according to topline data released by Clearside Biomedical. The Dogwood trial evaluated the safety and efficacy of CLS-TA (triamcinolone acetonide) in 22 patients with macular edema associated with noninfectious uveitis. A single treatment of CLS-TA resulted in a statistically significant mean change in central subfield thickness from baseline to 8 weeks. The secondary endpoint of statistical significance in mean increase from baseline in best corrected (Read more...)